Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) had its price target raised by equities researchers at Oppenheimer from $14.00 to $22.00 in a research report issued on Thursday, December 5th, The Fly reports. Oppenheimer’s target price would indicate a potential upside of 2.71% from the company’s current price. Oppenheimer also issued estimates for Aurinia Pharmaceuticals’ FY2023 earnings at $0.75 EPS.
Several other equities analysts have also recently commented on AUPH. Citigroup assumed coverage on Aurinia Pharmaceuticals in a research note on Monday, September 9th. They set an “outperform” rating and a $14.00 target price for the company. ValuEngine cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 10th. Royal Bank of Canada raised their price objective on Aurinia Pharmaceuticals from $11.00 to $20.00 and gave the stock an “outperform” rating in a research note on Thursday, December 5th. BidaskClub upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 30th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Aurinia Pharmaceuticals in a research note on Thursday, October 17th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $19.46.
Shares of Aurinia Pharmaceuticals stock remained flat at $$21.42 on Thursday. 1,572,043 shares of the company traded hands, compared to its average volume of 7,280,081. The business has a 50-day moving average of $11.94 and a two-hundred day moving average of $7.32. Aurinia Pharmaceuticals has a 1-year low of $3.52 and a 1-year high of $21.93.
A number of hedge funds and other institutional investors have recently made changes to their positions in AUPH. Vivo Capital LLC boosted its position in Aurinia Pharmaceuticals by 57.7% during the 2nd quarter. Vivo Capital LLC now owns 1,913,623 shares of the biotechnology company’s stock worth $12,592,000 after acquiring an additional 700,333 shares during the period. Orbimed Advisors LLC boosted its position in Aurinia Pharmaceuticals by 12.1% during the 2nd quarter. Orbimed Advisors LLC now owns 3,531,002 shares of the biotechnology company’s stock worth $23,234,000 after acquiring an additional 381,192 shares during the period. SG Americas Securities LLC acquired a new stake in Aurinia Pharmaceuticals during the 3rd quarter worth about $246,000. BlackRock Inc. boosted its position in Aurinia Pharmaceuticals by 3.1% during the 2nd quarter. BlackRock Inc. now owns 921,425 shares of the biotechnology company’s stock worth $6,063,000 after acquiring an additional 28,129 shares during the period. Finally, Virtu Financial LLC acquired a new stake in Aurinia Pharmaceuticals during the 3rd quarter worth about $122,000. Hedge funds and other institutional investors own 28.23% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
See Also: What is the Euro STOXX 50 Index?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.